A concise summary of the current evidence base for IV ketamine in treatment-resistant depression and related conditions, for primary care and behavioral-health colleagues considering referral. For patients with treatment-resistant depression (TRD) — roughly a third of the depressed population — rapid-acting glutamatergic agents have reshaped the treatment landscape. This brief summarizes what the recent literature says about subanesthetic IV ketamine, so you can counsel patie